3M-backed CNS disorder therapy developer Impel priced its initial public offering in the middle of its range, giving it a $290m market cap.

US-based central nervous system (CNS) disorder-focused drug developer Impel NeuroPharma floated on Friday in an $80m initial public offering representing an exit for manufacturing group 3M. The offering consisted of just over 5.3 million shares priced at $15.00 each, in the middle of the IPO’s $14 to $16 range, and they closed trading at the…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.